Vector heterologous COVID Vaccine

Go to article

Posted by on February 12, 2021 4:15 pm
Tags:
Categories: Column3

Vector heterologous COVID Vaccine

Source : The Lancet , (A) Receptor-binding domain-specific antibodies on day 42, as measured by ELISA, in participants administered with vaccine, by age group and overall, or placebo overall. (B) Neutralising antibodies on day 42, as measured by neutralisation assay with 100 TCID50, in participants administered with vaccine or placebo.

Leave a Reply

Your email address will not be published. Required fields are marked *

< AI TrueNEWS™ home